CD4 and breast carcinoma: In breast cancer, where neoadjuvant therapy is often the cornerstone of treatment, a decrease of CD4 + T lymphocytes24, and an increase of CD8 + T lymphocytes24,25 in comparison to the pre-treatment tissue specimen has been reported, suggesting an increase in tumor antigenicity after neoadjuvant chemotherapy24,25.